EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Convergent pathways of the hyperferritinemic syndromes

Grant S Schulert, Scott W Canna

International Immunology · 25.04.2018 · 30 (5) · 195-203

DOI: 10.1093/intimm/dxy012 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Immunology, online erschienen am 06.02.2018. Verfasst von Grant S Schulert und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. Die Arbeit wurde bisher 66-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, Rheumatology Research Foundation, Cincinnati Children’s Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hyperferritinemia and pronounced hemophagocytosis help distinguish a subset of patients with a particularly inflammatory and deadly systemic inflammatory response syndrome. Two clinically similar disorders typify these hyperferritinemic syndromes: hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS). HLH is canonically associated with a complete disturbance of perforin/granzyme-mediated cytotoxicity, whereas MAS occurs in the context of the related rheumatic diseases systemic juvenile idiopathic arthritis and adult-onset Still’s disease, with associated IL-1 family cytokine activation. In practice, however, there are accumulating lines of evidence for innate immune dysregulation in HLH as well as partial impairments of cytotoxicity in MAS, and these mechanisms likely represent only a fraction of the host and environmental factors driving hyperferritinemic inflammation. Herein, we present new findings that highlight the pathogenic differences between HLH and MAS, two conditions that present with life-threatening hyperinflammation, hyperferritinemia and hemophagocytosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnimalsCytotoxicity, ImmunologicHumansImmunity, InnateInflammationInterferon-gammaInterleukin-1Lymphohistiocytosis, HemophagocyticMacrophage Activation SyndromePhagocytosisSignal TransductionSyndrome

Substanzen

Interleukin-1Interferon-gamma

Autor:innen und Institutionen

  • Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
  • RK Mellon Institute for Pediatric Research, Pittsburgh, PA, USA.

Förderung

  • NIAID NIH HHS
  • Rheumatology Research Foundation
  • Cincinnati Children’s Research Foundation

Zitieren

APA

Schulert, G. S., & Canna, S. W. (2018). Convergent pathways of the hyperferritinemic syndromes. International Immunology, 30(5), 195-203. https://doi.org/10.1093/intimm/dxy012

Vancouver

Schulert GS, Canna SW. Convergent pathways of the hyperferritinemic syndromes. International Immunology. 2018;30(5):195-203. doi:10.1093/intimm/dxy012

BibTeX
@article{Schulert2018,
  author = {Schulert, Grant S and Canna, Scott W},
  title = {Convergent pathways of the hyperferritinemic syndromes},
  journal = {International Immunology},
  year = {2018},
  volume = {30},
  number = {5},
  pages = {195--203},
  doi = {10.1093/intimm/dxy012}
}
Kostenlos starten →